To appraise the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma multiforme.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 836
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Northwest Biotherapeutics (DCVax-L)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Brain Tumour Charity
- Brainstrust
- International Brain Tumour Alliance (IBTA)
- Professional groups
- Association of British Neurologists
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 April 2025 | Note - Note added to the project documents |
| 05 March 2024 | Note - Note added to the project documents |
| 23 December 2022 | Note added to the project documents |
| 22 December 2022 | In progress |
| 19 September 2018 | Note added to the project documents |
| 14 June 2018 | Invitation to participate |
| 03 April 2018 - 01 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 16 August 2017 | Note added to the project documents |
| 26 January 2017 - 23 February 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual